SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical trial NCT03113643 · RECRUITING
Trial details
- NCT number
- NCT03113643
- Sponsor
- Dana-Farber Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-26
- Primary completion
- 2021-09-15
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.